Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Deuteporfin Tolerance and Pharmacokinetics in Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Identifier:
First received: October 10, 2011
Last updated: May 14, 2012
Last verified: May 2012
Deuteporfin, a novel photodynamic drug developed in China, displays good photodynamic antitumor activity. The purpose of the present study is to investigate the safety and pharmacokinetics of intravenous deuteporfin in healthy Chinese volunteers following single-dose administration.

Condition Intervention Phase
Drug: deuteporfin
Drug: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Tolerance and Pharmacokinetics of Single-dose Intravenous Deuteporfin in Healthy Volunteers

Further study details as provided by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.:

Primary Outcome Measures:
  • number of participants with adverse events [ Time Frame: up to 19 days following injection ]
    number of participants with adverse events as a measure of safety and tolerability of single dose of deuteporfin administered to healthy subjects

Secondary Outcome Measures:
  • Pharmacokinetic profile [ Time Frame: predose, 20, 40 and 60 min during-dose, and 5, 10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8 ,12, 24h post-dose ]
    Pharmacokinetic profile: Cmax (Peak Concentration), AUC (area under the plasma-concentration-time curve ), T1/2 (half life)

Enrollment: 32
Study Start Date: November 2011
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: deuteporfin 1mg/kg Drug: deuteporfin
deuteporfin 1 mg/kg IV as a single dose
Active Comparator: deuteporfin 2.5mg/kg Drug: deuteporfin
deuteporfin 2.5 mg/kg IV as a single dose
Active Comparator: deuteporfin 5mg/kg Drug: deuteporfin
deuteporfin 5 mg/kg IV as a single dose
Active Comparator: deuteporfin 7.5mg/kg Drug: deuteporfin
deuteporfin 7.5 mg/kg IV as a single dose
Placebo Comparator: placebo Drug: placebo
Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Chinese healthy male and/or female subjects
  • 18 to 45 years old with Body mass index (BMI) within the range of 19 to 24 kg/m2
  • weigh at least 45 kg for female subjects or 50 kg for male subjects
  • In good health as confirmed by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis on the screening and baseline evaluation
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

  • Significant illness or major surgery within four weeks prior to dosing
  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies and photoallergy)
  • Use of any drugs which might interfere with drug absorption, distribution, metabolism, excretion or cause photoallergy within 30 days prior to dosing, or any drugs within 14 days prior to dosing
  • Participation in any clinical investigation within 30 days prior to dosing
  • Smokers, alcoholics, drug abusers
  • Immunodeficiency diseases, including a positive HIV test result, Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result
  • pregnancy or lactation for female subjects
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01481597

China, Hunan
Xiangya Hospital of Central-South University
Changsha, Hunan, China, 410008
Sponsors and Collaborators
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Principal Investigator: Zeneng Cheng, Ph.D Xiangya Hospital of Central South University
Study Director: Jining Tao, Master Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Principal Investigator: Pingsheng Xu, Master Xiangya Hospital of Central South University
  More Information

Responsible Party: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Identifier: NCT01481597     History of Changes
Other Study ID Numbers: FDZJ1109DT
Study First Received: October 10, 2011
Last Updated: May 14, 2012

Keywords provided by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.:
healthy volunteers processed this record on May 25, 2017